MeMed BV (Bacterial vs. Viral)

Host Response Immunoassay Test: Rapidly Distinguish Between Bacterial and Viral Infections

Bacterial and viral infections are often clinically indistinguishable, which can lead to inappropriate patient management and antibiotic misuse.1

MeMed BV® is a regulatory-cleared host-immune response assay for accurately distinguishing between bacterial and viral infections within the ED workflow in just 15 minutes. Together with the MeMed KeyTM immunoassay instrument, MeMed BV helps physicians make better decisions in the management of patients with acute infections in a timely manner.

Schedule a Demo

Overview
Documents
Education


 

Distinguish Between Bacterial and Viral Infections in Just 15 Minutes

With rapid, accurate host response information to differentiate between bacterial and viral infections, MeMed BV is decoding the body’s response to infection, helping clinicians make faster, more informed decisions.

Experience the Difference with MeMed BV

What makes MeMed BV stand apart from conventional testing?

  • No need to access the site of infection
  • Uses only a small sample of serum or venous whole blood*
  • Not affected by colonizers
  • Able to detect co-infections
  • <15 minutes to results

Three Biomarkers + Machine Learning = MeMed BV

The regulatory-cleared MeMed BV assay computationally integrates the levels of three host immune proteins—TRAIL, IP-10, and CRP—into a simple score that indicates the likelihood of a bacterial infection or co-infection versus a likely viral infection.

MeMed BV Performance

An FDA clinical study (Apollo) was conducted to establish the diagnostic performance of the MeMed BV test for differentiating bacterial from viral infection in patients with suspected acute bacterial or viral infection.4 They showed that implementing MeMed BV had the potential to reduce unnecessary antibiotic prescription 2.2-fold.

The Value of MeMed BV in the Management of Patients with Suspected Sepsis

Early differentiation between bacterial and viral infections offers additive diagnostic value on top of other existing tests and holds potential to improve antimicrobial stewardship.

Performance Independently Confirmed in Unprecedented Validation and Real-World Usage Encompassing >20,000 Patients

MeMed BV performance has been validated in multi-national, double-blind clinical studies and real-world settings enrolling more than 20,000 subjects in Europe, Israel, and the United States.4-14 These studies have consistently demonstrated compelling performance results in different clinical settings, age groups, and patients with different clinical syndromes.

Sort

MeMed Key

MeMed Key is an easy-to-use, compact immunoassay platform that makes it possible to conduct highly sensitive, quick, multiplexed protein measurements that previously could only be done on large, expensive central lab equipment. Together, MeMed Key and MeMed BV help physicians make better decisions in the management of patients with acute infections.

MeMed key rev

Host Response to Infection Solutions

Speak to a Representative about MeMed BV


*Use of MeMed BV with venous blood is 510k cleared, CE-marked, and approved by the Israeli Health Administration.

MeMed BV and MeMed Key are trademarks or registered trademarks of MeMed in the United States and other countries. Used under license. All other trademarks are the property of their respective owners.

Beckman Coulter is a distributor of MeMed BV. Not available in all markets. Please contact your local sales rep for more information about availability.

1. Oved K, Cohen A, Boico O, et al. A Novel Host-Proteome Signature for Distinguishing between Acute Bacterial and Viral Infections. PLoS ONE. 2015;10(3):e0120012. doi:10.1371/journal.pone.0120012

2. Centers for Disease Control and Prevention. Antibiotic use in the United States: Progress and opportunities, 2018 update. Centers for Disease Control and Prevention, Atlanta, GA. 2018.

3. Kornblith AE, Fahimi J, Kanzaria HK, Wang RC. Predictors for under-prescribing antibiotics in children with respiratory infections requiring antibiotics. The American Journal of Emergency Medicine. 2017;36(2):218-225. doi:10.1016/j.ajem.2017.07.081

4. MeMed data on file. Based on secondary endpoint analysis in Apollo Clinical Study (NCT04690569).

5. Oved K, Cohen A, Boico O, et al. A Novel Host-Proteome Signature for Distinguishing between Acute Bacterial and Viral Infections. PLoS ONE. 2015;10(3):e0120012. doi:10.1371/journal.pone.0120012

6. van Houten CB, De Groot J a H, Klein A, et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. The Lancet Infectious Diseases. 2016;17(4):431-440. doi:10.1016/s1473-3099(16)30519-9

7. Srugo I, Klein A, Stein M, et al. Validation of a novel assay to distinguish bacterial and viral infections. Pediatrics. 2017;140(4). doi:10.1542/peds.2016-3453

8. Eden E, Srugo I, Gottlieb T, et al. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. Journal of Infection. 2016;73(2):177-180. doi:10.1016/j.jinf.2016.05.002

9. Mor M, Paz M, Amir L, et al. Bacterial vs viral etiology of fever: A prospective study of a host score for supporting etiologic accuracy of emergency department physicians. PLoS ONE. 2023;18(1):e0281018. doi:10.1371/journal.pone.0281018

10. Papan C, Argentiero A, Porwoll M, et al. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: a prospective, multicentre cohort study. Clinical Microbiology and Infection. 2021;28(5):723-730. doi:10.1016/j.cmi.2021.10.019

11. Halabi S, Shiber S, Paz M, et al. Host test based on tumor necrosis factor-related apoptosis-inducing ligand, interferon gamma-induced protein-10 and C-reactive protein for differentiating bacterial and viral respiratory tract infections in adults: diagnostic accuracy study. Clinical Microbiology and Infection. 2023;29(9):1159-1165. doi:10.1016/j.cmi.2023.05.033

12. Chokkalla AK, Tam E, Liang R, Cruz AT, Devaraj S. Validation of a multi-analyte immunoassay for distinguishing bacterial vs. viral infections in a pediatric cohort. Clinica Chimica Acta. 2023;546:117387. doi:10.1016/j.cca.2023.117387

13. Kalmovich B, Rahamim-Cohen D, David SSB. Impact on Patient Management of a Novel Host Response Test for Distinguishing Bacterial and Viral Infections: Real World Evidence from the Urgent Care Setting. Biomedicines. 2023;11(5):1498. doi:10.3390/biomedicines11051498

14. Klein A, Shapira M, Lipman-Arens S, et al. Diagnostic Accuracy of a Real-Time Host-Protein Test for Infection. Pediatrics. 2023;152(6):e2022060441. doi:10.1542/peds.2022-060441